A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

References

• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–1163.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, . Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896–903.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Osenkoppele GJ, van Putten W, . High dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;36:1235–1248.
   Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, . Attempts to improve outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302–1311.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, . On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268–1274.
   PubMed Web of Science ®Google Scholar
• Tilly H. Low dose Ara-C versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272–279.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, . A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114–1124.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia – new agents. Semin Hematol 2006;43: 96–106.
   PubMed Web of Science ®Google Scholar
• Stirewalt DLand Radich JP. The role of FLT3 in hematopoietic malignancy. Nat Rev Cancer 2003:3:650–655.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752–1759.
   PubMed Web of Science ®Google Scholar
• Whitman SP, Archer KJ, Feng L, . Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001;61: 7233–7239.
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. The pathophysiologic role of VEGF in hematological malignancies: therapeutic implications. Blood 2005;105:1383–1395.
   PubMed Web of Science ®Google Scholar
• Schuch G, Machluf M, Bartsch G Jr . In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002;100:4622–4628.
   PubMed Web of Science ®Google Scholar
• Staber PB, Linkesch W, Zauner D, . Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 2004;23:894–904.
   PubMed Web of Science ®Google Scholar
• Karp JE, Lancet JE, Kaufmann SH, . Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361–3369.
   PubMed Web of Science ®Google Scholar
• Zimmerman TM, Harlin H, Odenike OM, . Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol 2004;22:4816–4822.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Chien DS. Sorafenib: preclinical data. Curr Pharm Des 2002;8:2255–2257.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, . Sorafenib exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Meng XW, Lee SH, Dai H, . Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007;282:29831–29846.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Davis EM, Bauer C, . Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280:35217–35227.
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek LM, Meng XW, . The role of Mcl-1 in downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861–6869.
   PubMed Web of Science ®Google Scholar
• Hu S, Niu H, Inaba H, . Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011;103:893–905.
   PubMed Web of Science ®Google Scholar
• Crump M, Hedley D, Kamel-Reid S, . A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010;51:252–260.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.
   PubMedGoogle Scholar
• Cheson BD, Cassileth PA, Head DR, . Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813–819.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, . Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–3674.
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C, . The impact of FLT3internal tandem duplication level, number, size, and interaction with NPM1mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776–2784.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Cho E, Karp J, . Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol 2009;27(15 Suppl.):Abstract 7065.
   Google Scholar
• Borthakur G, Kantarjian H, Ravandi F, . Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96:62–68.
   PubMed Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E, . Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567–6571.
   PubMed Web of Science ®Google Scholar